Celldex Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $63.07. The average 1-year stock price forecast is 112.29% higher than the current stock price, while the lowest is $28 (-5.76%) and the highest is $100 (+236.59%).

Price Target: $63.07 (+112.29%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$28	$63.07	$64	$100
Change	-5.76%	+112.29%	+115.42%	+236.59%

Analyst Ratings

The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	12	13	13	13	12	12
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	16	16	16	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Reiterates $57	Buy	Reiterates	$57	+91.85%	Oct 20, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Maintains $72	Buy	Maintains	$72	+142.34%	Oct 15, 2026
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $61 → $72	Buy	Maintains	$61 → $72	+142.34%	Oct 14, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Hold Maintains $38 → $28	Hold	Maintains	$38 → $28	-5.76%	Oct 5, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $64	Buy	Reiterates	$64	+115.42%	Oct 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.85M

from 1.55M

19.74%

from 1.55M

Revenue Next Year

8.76M

from 1.85M

373.52%

from 1.85M

EPS This Year

-4.12

from -3.90

EPS Next Year

-4.25

from -4.12

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	4.65M	2.36M	6.88M	7.02M	1.55M	1.85M
Revenue Growth	-37.30%	-49.32%	192.02%	1.99%	-77.99%	19.74%
Operating Income	-69.15M	-107.10M	-142.04M	-195.08M	-287.37M	-337.64M
Net Income	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M	-319.17M
EPS	-	-	-	-	-3.90	-4.12
Free Cash Flow	-	-	-	-	-213.66M	-275.00M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	6.5M
Avg	1.8M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	320.7%
Avg	19.7%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.71
Avg	-4.12
Low	-4.33

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-